Bronchial asthma as neurogenic paroxysmal inflammatory disease: A randomized trial with carbamazepine
Received 3 November 2005; accepted 20 February 2006. published online 06 April 2006.
Summary
Purpose
Based on the assumption that bronchial asthma has not only inflammatory, but also certain neurogenic paroxysmal mechanism and pathophysiological links with other non-epileptic paroxysmal inflammatory diseases—migraine and trigeminal neuralgia, we decided to investigate efficacy of antiepileptic drug carbamazepine in patients with moderate persistent or severe asthma.
Stable remission was achieved after carbamazepine treatment in 25 patients in active group (). No significant improvement was registered in patients of placebo group (). Following open-label treatment shows high and stable antiasthmatic efficacy of carbamazepine monotherapy.
Conclusions
Carbamazepine showed high efficacy in therapy of moderate persistent or severe bronchial asthma. Antiasthmatic activity of carbamazepine can be considered as influence on neurogenic mechanisms of asthma. We suppose that it is possible to use carbamasepine for therapy of bronchial asthma in clinical practice.
ABSTRACT
